SIGA TECHNOLOGIES INC (SIGA) SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
SIGA Technologies, Inc. NASDAQ:SIGA Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $218.42M
Div Yield 19.74%
Mkt Cap $218.42M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Div Yield 19.74%
Press Release
SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results
SIGA Technologies announced it will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Monday, November 9, 2026, following the release of its third-quarter 2026 financial results.
CEO Diem Nguyen and CFO Daniel Luckshire will lead the call, which will be webcast live on the company's Investor Relations site with a replay available for two weeks.
The notice contains no financial results or guidance; it is purely a scheduling announcement ahead of the Q3 print.
• 3d ago AI analysis › Press Release ⚠ 1
SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®
SIGA won a new Canadian government contract worth up to approximately $15 million to supply oral TPOXX to the Canadian Department of National Defence, with deliveries through March 31, 2031.
Approximately $9 million is firmly committed over the first three years, with the remaining ~$6 million contingent on CDND option exercises. This is the second PSPC contract for TPOXX, following a ~$14 million award in April 2020 that was fully delivered by 2025.
The award adds to SIGA's international biodefense revenue base, though its near-term dollar value is small relative to the company's U.S. BARDA contract exposure.
• 4d ago AI analysis › Press Release ● Major ⚠ 2
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
SIGA reported Q2 2026 revenue of $41.0 million and diluted EPS of $0.17, reflecting a roughly 50% decline compared to the prior year.
The decrease follows the completion of the final procurement order under the 19C BARDA contract, though the company delivered $37 million of TPOXX to US and international customers.
During the quarter, the company paid a special dividend of $0.60 per share and generated $12.5 million in net income.
• 2mo ago AI analysis › Press Release
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA announced it will host a business update and conference call on August 6, 2026, to discuss second-quarter 2026 financial results.
The webcast and call will feature CEO Diem Nguyen and CFO Daniel Luckshire, beginning at 4:30 P.M. ET.
Investors can access the live event via the company website or telephone, with a replay available for two weeks post-event.
• 3mo ago AI analysis › Press Release ● Major
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
globenewswire.com • 5mo ago Press Release ● Major
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
globenewswire.com • 6mo ago 
